Congratulations to our Students!22 July 2015The School is delighted to congratulate its undergraduate students from all years on an excellent set of examination results, perpetuating the strength and reputation of the Bristol Biochemistry degree programmes.
Cancer surgery or biopsy collection could influence disease progression2 July 2015Scientists at Bristol Biochemistry studying the body’s inflammatory response to wounds following cancer surgery or biopsy have found that these procedures may cause growth signals to be delivered to any remaining cancer or pre-cancerous cells which may negatively influence disease progression.
Bristol Biochemistry Academic Scoops Two Teaching Awards26 June 2015The winners of the 2015 Bristol Teaching Awards have been announced on Monday 15th June. The Bristol Teaching Awards are a joint venture between the University of Bristol and Bristol SU (the Students’ Union). The Awards are to recognise the most outstanding members of staff who have delivered exceptional contributions to teaching and supporting students.
Human trials of manufactured blood within two years25 June 2015The first human trials of lab-produced blood to help create better-matched blood for patients with complex blood conditions has been announced by NHS Blood and Transplant. Research led by scientists at the University of Bristol and NHS Blood and Transplant, used stem cells from adult and umbilical cord blood to create a small volume of manufactured red blood cells.
ESCRT-III controls nuclear envelope reformation4 June 2015Mitosis is the process by which eukaryotic cells divide up their chromosomes and form two genetically identical daughter cells. It involves a series of highly co-ordinated steps mediated by a plethora of proteins. During the final stages of mitosis (telophase) the nuclear envelope reassembles around the segregated chromosomes in a two-step process first involving the coating of chromatin by membranes from the endoplasmic reticulum followed by annular fusion of these membranes together to create a sealed barrier. Staff and Facilities of the School of Biochemistry collaborated with King's College London to investigate this, culminating in a publication in Nature.
Molecular basis of rapamycin insensitivity of Target Of Rapamycin Complex 2 revealed1 June 2015In eukaryotes, cell growth and division is stimulated by the availability of nutrients, presence of growth factors and of other cells. One of the key factors controlling cell growths is Target Of Rapamycin (TOR), a conserved, atypical protein kinase which is an important cancer therapeutic target and which is inhibited by the immunosuppressive, anti-proliferative drug rapamycin in complex with the FKBP12 protein. Decreased TOR activity has been found to increase life span in S. cerevisiae, C. elegans and mice. TOR kinase is part of two very large multi-protein complexes: rapamycin-sensitive TOR complex 1 (TORC1) and rapamycin-insensitive TOR complex 2 (TORC2). Why TORC2 is insensitive to rapamycin has been a longstanding mystery in the TOR field. In a paper published by Molecular Cell, this essential question has now been answered.